Clinical trial
A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Chronic…
NCT00304551 · Chugai Pharmaceutical, Industry · Completed
Key facts
| NCT number | NCT00304551 |
|---|---|
| Title | A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Chronic Hepatitis C (CHC) Patients With Compensated Liver Cirrhosis (LC) |
| Official title | A Phase II/III Study of Peginterferon Alfa-2a in Combination With Ribavirin for the Treatment of CHC With Compensated LC |
| Lead sponsor | Chugai Pharmaceutical, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Liver Cirrhosis, Chronic Hepatitis C |
| Intervention type | Drug |
| Interventions | peginterferon alfa-2a 180μg, peginterferon alfa-2a 90μg, ribavirin |
| Enrollment | 180 |
| Start date | Jun 1, 2006 |
| Primary completion | Dec 1, 2009 |
| Completion | Jun 1, 2010 |
| First posted | Mar 20, 2006 |
| Last update posted | Jun 3, 2010 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: